MBBS, PhD, FRACP
Professor Mann is co-Director of the Centre for Cancer Research, Westmead Institute for Medical Research, in Sydney Medical School.
Professor Mann has an international reputation in the genomics and genetic epidemiology of melanoma, and in translational oncology. Many of his outputs arise from highly productive research consortia and multidisciplinary and inter-disciplinary partnerships. He is co-PI of the Australian Melanoma Genome Project, and a member of the Scientific Steering Committee of the International Cancer Genome Consortium. He has served on the NHMRC Health Care Committee (2012-2015), and co-chaired a NHMRC Research Translation Faculty Steering Group.
He has contributed strongly to the establishment, development and leveraging of the data and tissue resources of the Melanoma Institute Australia, and these are now supporting a wide variety of applied and translational genomics studies of biomarkers and molecular targets. His principal impacts on practice to date have been in establishing the framework for genetic risk assessment in familial melanoma internationally and the banning of commercial sunbeds in Australia. He leads the chapter on high-risk individuals for the NHMRC/CCA Clinical Practice Guidelines on Melanoma.
In the Centre of Research Excellence in Melanoma Prof Mann is the leader of the CRE Core 1: Identifying and managing people at high risk of developing melanoma.
PhD, MPH(Hons), BSc, BA
Associate Professor Cust is Head of the Cancer Epidemiology and Prevention Research Group in the Sydney School of Public Health and co-lead of the 'Prevention and individuals at high risk of melanoma' research theme at the Melanoma Institute Australia, The University of Sydney. Her position is funded through Career Development Fellowships from the National Health and Medical Research Council (NHMRC) and the Cancer Institute NSW.
She is an internationally recognised cancer epidemiologist with expertise in collaborative, multidisciplinary research with a strong emphasis on translational outcomes. Her research predominantly focuses on melanoma prevention, early detection and survivorship. She leads programs of research on melanoma risk prediction, risk-stratified cancer prevention and screening, and the genetic epidemiology of melanoma. In collaboration with Professor Mann, A/Prof Cust led the sunbed research that was instrumental in informing government bans on commercial solaria now in effect across all states of Australia, and received an inaugural Sax Institute Research Action Award to recognise this research and translation efforts.
She is President of the Australasian Epidemiological Association and a member of the Executive of several cancer groups including the Australia and New Zealand Melanoma Trials Group (ANZMTG), Clinical Oncology Society of Australia (COSA) Exercise and Cancer Group, and COSA Epidemiology Group. She is actively involved in international melanoma consortia, including the GenoMEL (Genetics of Melanoma) Analysis Team, the GEM (Genes, Environment and Melanoma) Steering group, and the InterMEL (Integration of Clinical and Molecular Biomarkers for Melanoma Survival) Investigator team.
She contributed to the chapter on high-risk individuals for the NHMRC/CCA Clinical Practice Guidelines on Melanoma and has authored chapters for internationally renowned melanoma textbooks.
In the Centre of Research Excellence in Melanoma Associate Professor Cust is the co-leader of the CRE Core 1: Identifying and managing people at high risk of developing melanoma, and will contribute to the work of all Cores.
BMedSci, MBBS, MD FRCPA FRCPath FAHMS
Prof Scolyer is Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; Co Medical Director, Melanoma Institute Australia; and Clinical Professor, The University of Sydney. Richard studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. He provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2000 cases for opinion from Australasia and beyond annually.
Professor Scolyer effectively integrates his clinical practice with leading an award winning translational melanoma research laboratory. His record includes co-authoring more than 500 publications including in prestigious journals such as the New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery. Richard has presented on more than 300 occasions at conferences throughout the world. In 2006, Professor Scolyer was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received NSW Premier's Awards for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017, 2018 and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category, and the 2018 Research Australia’s GSK Award for Research Excellence
His publications have received most highly cited awards on 5 other occasions. According to Thomson Reuters ISI Web of Knowledge, Richard is the highest ever published scientist in the world in the field of melanoma pathology and he also has the highest H index in this field. The Fame Report (2011) published by Medical Experts International (www.medexpert.com) ranked him the 6th leading melanoma expert in any field or discipline worldwide and the highest ranked melanoma pathologist worldwide. In January 2018, he was ranked the world's 11th leading melanoma expert in any field or discipline and the world's leading melanoma pathologist (http://expertscape.com/ex/melanoma).
In 2016, Richard was appointed an editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume in which he was the responsible editor for 3 of the 6 sections and authored/co-authored more than 30 chapters. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of AJCC Cancer Staging System, co-leads the Australian Melanoma Genome Project (part of the International Cancer Genome Consortium) (Nature 2017), was lead pathologist for the NIH funded The Cancer Genome Atlas (TCGA) Melanoma Project (Cell, 2015), chairs the Melanoma Expert Panel for the International Collaboration on Cancer Reporting, and lead pathologist/member of the overseeing Management Committee, Multidisciplinary Working Party and Author for the Australian Melanoma Clinical Practice Guidelines and a lead author of the College of American Pathologists Melanoma Reporting protocol.
He is also an editorial board member of the American Journal of Surgical Pathology, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology and a number of other international journals. Richard is the current Immediate Past President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, he is chief investigator on a 5 year NHMRC program grant and has a personal Fellowship from the NHMRC.
In the Centre of Research Excellence in Melanoma Prof Scolyer is executive committee member and co lead Core 2
PhD, FAIM, FCHSM, FFPHRCP, FAcSS, Hon FRACMA, FAHMS
Professor Braithwaite is Founding Director of the Australian Institute of Health Innovation, Director of the Centre for Healthcare Resilience and Implementation Science, and Professor of Health Systems Research, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
Professor Braithwaite is a leading health services and systems researcher with an international reputation for his work investigating and contributing to systems improvement and implementation science. He has particular expertise in the culture and structure of acute settings, leadership, management and change in health sector organisations, quality and safety in healthcare, accreditation and surveying processes in international context and the restructuring of health services. He is the recipient as at 2018 of career research funding of over $110.7 million spread over 76 grants; total new research funding and grants in the last five years amounts to over $66.6million; more than 80% of this grant funding is category one, peer-reviewed, chiefly ARC and NHMRC funding.
He has appointments at six other universities internationally; is a board member and President Elect of the International Society for Quality in Health Care (ISQua) and consultant to the World Health Organisation (WHO). Professor Braithwaite is well known for bringing management and leadership concepts and evidence into the clinical arena and he has published extensively (more than 450 refereed contributions, and 900 total publications).
In the Centre of Research Excellence in Melanoma Prof Braithwaite is working across all cores, but primarily CRE Core 2: Leading the development of skills in implementation science across the CRE, Sentinel node biopsy study.
AM, MD, MBBS, FACD
Founder of the Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia
Professor John Kelly founded one of Australia's largest multidisciplinary treatment services for melanoma, the Victorian Melanoma Service, at the Alfred hospital in 1994 and remained it's Director till 2018. He trained as a dermatologist in Melbourne and undertook his Doctorate at the Melanoma Clinic, University of California, San Francisco, on the subject of melanoma diagnosis and management.
Major areas of research have been in the area of melanocytic naevi, clinical techniques for the early detection of melanoma, atypical presentations of melanoma and aggressive primary melanoma. The over-arching theme has been to reduce melanoma deaths by facilitating early detection. He has pursued each topic with a series of research projects that have contributed important findings of clinical significance.
Professor Kelly has served on the board of the Australia and New Zealand Melanoma Trials Group, and is a member of the Executive Steering Committee and contributing author for the wiki-based Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma 2017.
In the Centre of Research Excellence in Melanoma Prof Kelly contributes to CRE Core 1: Identifying and managing people at high risk of developing melanoma.
MScMed(Clin Epi)(Hons), PhD
Associate Professor Morton is Director of Health Economics and Deputy Director of Research at the NHMRC Clinical Trials Centre, University of Sydney. She is an investigator at the Melanoma Institute Australia (MIA) and Executive member of the Melanoma Clinical Outcomes Registry (MelCOR).
Associate Professor Morton has an international reputation in the economic evaluation of melanoma diagnosis, treatment and monitoring. She leads within-trial and modelled cost-effectiveness analyses to inform policy decision making on the basis of patient-centred and economic outcomes.
Her current projects alongside randomised trials include evaluation of genomic information for melanoma prevention; extensive lymph node surgery; whole brain radiotherapy for treatment of melanoma brain metastases; and evaluation of a psychoeducational intervention to prevent fear of cancer recurrence. She leads a program of research into the costs and benefits of CT and PET/CT monitoring, and the incorporation of patient reported outcomes measures (PROMs) into clinical quality registries.
A/Prof Morton served on the board of the Australia and New Zealand Melanoma Trials Group (ANZMTG) for 9 years, and prior to this managed the MIA Clinical Trials Unit. She is a regular discussant for the Economic Sub-Committee of the PBAC, and leads the chapter on diagnostic tests and follow-up for the NHMRC/CCA Clinical Practice Guidelines on Melanoma.
In the Centre of Research Excellence in Melanoma A/Prof Morton is the leader of the CRE Core 4: Health Economics and Policy
MD FRACS B Med Sci BMBS GAID
Professor of Surgical Oncology at The University of Sydney, Northern Clinical School.
Andrew's current research interests investigate issues around quality assurance in surgery, safe introduction of new surgical techniques and promoting clinical trial involvement by surgeons. He is heavily involved in clinical and translational research on aspects of melanoma and breast cancer. He is one of the leaders on the international primary melanoma width of margins study MelMART-2 that aims to determine the most appropriate surgical margins to maximise health outcomes whilst minimising morbidity.
He is CIA for the EAGLE FM clinical trial, which aims to define a the appropriate management of metastatic melanoma in the groin lymph nodes. He is a lead author and committee member for the new Cancer Council Australia Melanoma Guidelines. He has authored about 130 peer reviewed publications and co-authored 4 book chapters. He lectures and teaches junior doctors and students at the University of Sydney's, Northern Clinical School.
In the Centre of Research Excellence in Melanoma Andrew is co-leader of Core 2 - The patient with curable, early stage melanoma. He is involved in the evaluation and broader implementation of sentinel node biopsy for accurately staging melanoma patients at the time of diagnosis of their early stage melanoma.
FRACS, MS, MBBS
Associate Professor Saw is Head of Department, Melanoma and Surgical Oncology, RPAH; A/Prof, Discipline of Surgery, USyd; Clinical Academic and General Surgeon, Department of Melanoma and Surgical Oncology, RPAH; and, Faculty Member and Chair of the Education Committee Melanoma Institute Australia (MIA).
Robyn Saw is a Surgical Oncologist with the MIA and has a specific interest in the surgical and psycho-social management of melanoma and skin cancer. She leads major research projects on vitamin D, quality of life and survivorship. She has a strong focus on consumer engagement, in 2012-2015 coordinating the development, text and layout of an early-stage melanoma booklet and stage III melanoma patient information packs, and supervising the dissemination of the packs Australia-wide. She co-led the Melanoma Information Day educational events at MIA for patients and their carers 2012-2015. She is passionate about educating clinicians, and has been invited numerous times to speak to GPs and other clinicians about surgery and lymphoedema in melanoma. Her focus on education has led to her recent appointment as MIA Chair of the Education Committee.
In the Centre of Research Excellence in Melanoma Prof Saw will be assisting in the development of Core 2 (optimising management of early stage melanoma) and Core 3 projects.
MBBS, BMedSc, MD, FRACS
Is the deputy director division of cancer surgery at the Peter MacCallum Cancer Centre in Melbourne. His undergraduate education was at the University of Melbourne and surgical training at St Vincent's Melbourne. This was followed by a Surgical Oncology Fellowship at the University of Texas, MD Anderson Cancer Centre in Houston. His surgical practice is limited to surgical oncology and predominantly the management of patients with cutaneous malignancy. Currently he is head of the multidisciplinary Melanoma and Skin Service at the Peter MacCallum Cancer Centre.
Prof Henderson has had a long-standing interest in clinical and translational research. currently he is the lead for a number of multicentre studies at the Peter MacCallum Cancer Centre including Multicentre Selective Lymphadenectomy Trial 2 (MSLT2), Melanoma Margins of Excision Trial (MELMART). He is a participant in the Melbourne Melanoma Project which contributed to the recent update of the American Joint Commission on Cancer Melanoma Staging System (version 8). Currently he is co-supervising 3 higher degree students with colleagues from the research division at the Peter MacCallum Cancer Centre. He has published over 100 papers in the scientific literature and contributed chapters to 15 textbooks. He is on the working party of the Australian Cancer Society Guidelines for the Management Of Cutaneous Melanoma. Current clinical research interests include management of elderly patients with melanoma particularly the very elderly (more than 85 years of age), subungual melanoma, isolated infusion for in-transit metastasis and surveillance of patients with early stage melanoma. He was the lead investigator for the ANZMTG-TROG international multicentre randomised trial of adjuvant radiotherapy after lymphadenectomy which led to practice changing refinement of the role of adjuvant radiation. Further evaluation of results from this trial is ongoing including a detailed prospect of evaluation of the morbidity of lymphadenectomy. Currently he is the national lead investigator for the proposed ANZMTG International randomised trial of 1 cm versus 2 cm margins for melanomas > 2 mm in thickness.
In the Centre of Research Excellence in Melanoma Professor Henderson will work across cores, but primarily CRE Core 2: with his colleagues in Victoria and at the Peter MacCallum Cancer Centre he will work to support the aims of the CRE specifically focusing on surgical aspects of the management of early melanoma.
Professor in Statistics, School of Mathematics and Statistics, University of Sydney Theme Leader for Integrative System and Modelling | Charles Perkins Centre
Professor Jean Yang is an applied statistician with expertise in statistical bioinformatics. She was awarded the 2015 Moran Medal in statistics from the Australian Academy of Science in recognition of her work on developing methods for molecular data arising in cutting edge biomedical research. Her research stands at the interface between medicine and methodology development and has centered on the development of methods and the application of statistics to problems in -omics and biomedical research. In particular, her focus is on developing methods for integrating omics and clinical data to answer a variety of scientific questions. As a statistician who works in: statistical bioinformatics; applied statistics; statistical machine learning; complex data analytics and integrative analysis of omics data.
She enjoys research in a collaborative environment, working closely with scientific investigators from diverse backgrounds.
In the Centre of Research Excellence in Melanoma Prof Yang will be working on Core 2: Identify biomarkers for patient with curable, early stage melanoma Statistical and bioinformatics expertise